Changing Course, Applied Proteomics to Offer Colon Test via Mass Spec Instead of Immunoassay | GenomeWeb

Protein biomarker firm Applied Proteomics has decided to use multiple-reaction mass spectrometry as the platform for its clinical proteomic tests, John Blume, the company's chief science officer, told ProteoMonitor this week.

The decision marks a switch from the firm's original plan to convert its tests to an immunoassay platform for commercialization and serves as another example of growing industry confidence in mass spec as a viable clinical technology.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.